drugset
drugset / Trial / NCT01268527

A 12-Day Randomized, Blinded, Vehicle and Active Comparator-Controlled Study to Determine the Efficacy and Safety of Six Concentrations of Topical E6201 Gel in Subjects With Psoriasis Vulgaris

NCT01268527 ↗

Phase 2 Completed 30 enrolled Eisai Inc.
RandomizedParallel-groupTreatment

Summary

The purpose of this study is to investigate the efficacy, safety, tolerability and the concentration/response relationship of E6201 in subjects with psoriasis vulgaris.

Timeline

Start
2010-03-15
Primary completion
2010-12-11
Completion
2010-12-11

Drugs

EvaluationDrugModalityDoseRoute
Subject Calcipotriol Small molecule 0.005 % Topical
Subject E6201 Small molecule 0.005 % Topical
Subject E6201 Small molecule 0.01 % Topical
Subject E6201 Small molecule 0.03 % Topical
Subject E6201 Small molecule 0.05 % Topical
Subject E6201 Small molecule 0.1 % Topical
Subject E6201 Small molecule 0.2 % Topical

Indications

psoriasis